Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

GlobeNewswire March 10, 2022

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

GlobeNewswire March 3, 2022

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

GlobeNewswire February 21, 2022

Autolus Therapeutics announces retirement of chief financial officer and succession plan

GlobeNewswire January 10, 2022

Autolus Therapeutics announces 2022 priorities

GlobeNewswire January 10, 2022

Autolus Therapeutics to Present at Conferences During January 2022

GlobeNewswire January 5, 2022

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

GlobeNewswire December 13, 2021

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

GlobeNewswire December 6, 2021

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

GlobeNewswire November 15, 2021

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

GlobeNewswire November 10, 2021

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

GlobeNewswire November 8, 2021

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

GlobeNewswire November 4, 2021

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress

GlobeNewswire November 3, 2021

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

GlobeNewswire October 25, 2021

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

GlobeNewswire September 16, 2021

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

GlobeNewswire September 15, 2021

Autolus Therapeutics to participate in upcoming virtual investor conferences

GlobeNewswire September 2, 2021

Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology

GlobeNewswire September 1, 2021

Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

GlobeNewswire August 9, 2021

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress

GlobeNewswire August 5, 2021